Zurich axes spending to boost profits
November 21 2016 by InsuranceAsia News
-
Fidelidade Macau improves ROE on China border reopening, light rail transit project: Fitch
- November 22
The rating agency has affirmed the P&C carri rating at 'A' (strong) with a stable outlook driven by the insurer's strategic importance to its Portuguese parent company.
-
India invites consultants for feasibility study to set up P&I club
- November 22
The country's maritime authority has issued a tender to appoint a consultancy firm to conduct the study to set up a domestic insurance entity.
-
Australian doctors’ mutual MDA National appoints Tim Plant as chief executive
- November 22
Sydney-based Plant previously held senior executive roles at organisations including Elders, QBE, icare, Zurich, and, most recently, IAG.
-
Aon names Mike Yao as Asia director for life reinsurance analytics
- November 22
In his new role, Singapore-based Yao will contribute to the development and articulation of the broker's analytics value proposition for its APAC clients.
-
BHSI | Managing non-Asian exposure in long-tail lines
While US-exposed business can look attractive to Asian carriers, managing the volatility around the long-term results and the ability to model those losses are crucial, say BHSI’s Marc Breuil and Marcus Portbury.
-
Sedgwick | To Handle CAT Claims Well, Multi-Step Preparation is Key
When it comes to risk, it’s not a matter of “if” it’s a matter of “when” an event will occur.
-
HSBC Asset Management | Is it time to relook at Asian currency bonds?
With diversification and performance high on investors’ agendas, it seems a good time for global portfolios to revive allocations in Asian local currency bonds – including Hong Kong dollar (HKD) bonds.
-
PineBridge Investments | Why Asian insurers are exploring private credit and CLOs
The recent rollout of risk-based capital regimes across Asia calls for a closer alignment between insurers’ assets and liabilities. We explore potential ways to maintain a healthy investment yield and robust returns on regulatory capital.
